COVID-19 is a respiratory illness that also causes inflammation, but a third of hospitalized coronavirus patients develop dangerous blood clots as well. Scientists at Britain's Imperial College London hypothesize that the clots are a byproduct of a hormonal imbalance caused by an enzyme the coronavirus deactivates to invade cells, BBC News reports, and they are preparing a clinical trial to see if the experimental drug TRV027 can fix that imbalance. The trial, funded by the British Heart Foundation, begins next month, with about 60 patients getting either TRVO27 or a placebo.
TRVO27, made by Trevena, "works to rebalance hormones involved in blood pressure, water, and salt," BBC News says. It was originally developed to treat acute heart failure, though it failed to live up to expectations in a trial.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
-
Kim Kardashian's Met Gala corset: designed for drama but a step too far?In The Spotlight Reality TV star shocks with 'impossibly tiny waist' at this year's fashion event, echoing controversies from previous outfits
-
The Buddha of Suburbia: an 'orgiastic odyssey'The Week Recommends Emma Rice brings Hanif Kureishi's 1990 novel to the stage
-
'US tests ties with Israelis'Today's Newspapers A roundup of the headlines from the US front pages
-
Empty-nest boomers aren't selling their big homesSpeed Read Most Americans 60 and older do not intend to move, according to a recent survey
-
Brazil accuses Musk of 'disinformation campaign'Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
-
Disney board fends off Peltz infiltration bidSpeed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
-
Disney and DeSantis reach detenteSpeed Read The Florida governor and Disney settle a yearslong litigation over control of the tourism district
-
Visa and Mastercard agree to lower swipe feesSpeed Read The companies will cap the fees they charge businesses when customers use their credit cards
-
Reddit IPO values social media site at $6.4 billionSpeed Read The company makes its public debut on the New York Stock Exchange
-
Housing costs: the root of US economic malaise?speed read Many voters are troubled by the housing affordability crisis
-
Feds cap credit card late fees at $8speed read The Consumer Financial Protection Bureau finalized a rule to save households an estimated $10 billion a year
